Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies

@article{Gibson2006CancerCD,
  title={Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies},
  author={R. Gibson and D. Keefe},
  journal={Supportive Care in Cancer},
  year={2006},
  volume={14},
  pages={890-900}
}
BackgroundDiarrhoea and constipation are common toxicities of chemotherapy, and both are poorly understood. They are manifestations of alimentary mucositis, a condition which affects the entire gastrointestinal tract.DiscussionThe absolute percentage of patients that have diarrhoea or constipation as a result of their treatment has yet to be fully defined, although general estimates place 10% of patients with advanced cancer as being afflicted. Although there has been some major progress in… Expand

Paper Mentions

Interventional Clinical Trial
A 24-week, (two 12-week stages), randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of crofelemer in providing prophylaxis of diarrhea in adult… Expand
ConditionsAdult Solid Tumor, Cancer Therapy-Related Diarrhea, Chemotherapy-related Diarrhea, (+3 more)
InterventionDrug
Chemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging Treatments
TLDR
Identification of potential targets for novel therapies to alleviate chemotherapy-induced toxicity is essential to improve clinical outcomes and quality of life amongst cancer sufferers. Expand
Chemotherapy-induced diarrhoea
TLDR
The shift towards more effective research into diarrhoea caused by chemotherapy is highlighted, with many new treatment options trialled for ameliorating chemotherapy-induced diarrhea. Expand
Anti-Colorectal Cancer Chemotherapy-Induced Diarrhoea: Current Treatments and Side-Effects
TLDR
This work provides a review of chemotherapy-induced diarrhoea, current management guidelines, and shortcomings of current treatments as well as emerging and already existing anti-diarrhoeal treatments potentially suitable for CID. Expand
Emerging drugs for chemotherapy-induced mucositis
TLDR
There are many agents in varying stages of development for chemotherapy-induced mucositis, and the field is complicated by the question of whether treatments should be developed as drugs or as medical foods, and whether the burden of proof of efficacy and safety should be different. Expand
Chemotherapy-Induced Gastrointestinal Dysfunction and Enteric Neuropathy
TLDR
This thesis aims to uncover the effects of in vivo administration of anti-cancer chemotherapeutics oxaliplatin, 5-fluorouracil and irinotecan on the enteric nervous system and GI function, and examine the neuroprotective efficacy of a cytoprotective agent BGP-15. Expand
Gastrointestinal consequences of cancer treatment and the wider context: A bad gut feeling
TLDR
As the understanding of consequences of cancer treatments continues to emerge and encompass a wide variety of specialties, a holistic, multifaceted and multidisciplinary approach is required to manage those consequences long-term. Expand
Guidance on the management of diarrhoea during cancer chemotherapy.
TLDR
Practical guidance for clinicians is developed based on a literature review by a multidisciplinary team of clinical oncologists, dietitians, gastroenterologists, medical oncologist, nurses, pharmacist, and a surgeon on how to manage chemotherapy-induced diarrhoea. Expand
Chemotherapy-induced modifications to gastrointestinal microflora: evidence and implications of change.
TLDR
A review will explore the potentially important relationship between intestinal microflora and the subsequent development of chemotherapy-induced mucositis. Expand
Impact of chemotherapy on gastrointestinal functions and the enteric nervous system.
TLDR
The enteric nervous system is highlighted as a potential therapeutic target to alleviate chemotherapy-induced toxicity which may improve both clinical outcomes and the quality of patients' lives. Expand
VSL#3 probiotic treatment reduces chemotherapy-induced diarrhoea and weight loss
TLDR
VSL#3 is effective at preventing severe diarrhoea following chemotherapy with irinotecan and therefore has potential to be used clinically by cancer patients. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 86 REFERENCES
Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea.
TLDR
Symptom management has become a focus of clinical research, and development of personalised medicine should identify patients at increased risk of toxic effects because of molecular or biochemical factors, thus leading to changes in dose, early intervention, or use of alternative therapies. Expand
Constipation in advanced cancer patients
Constipation is a frequent, distressing, and underestimated complication in patients with advanced cancer. It may develop from general disturbances that may or may not be cancer related, but the useExpand
Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity.
TLDR
A hypothesis is proposed as to the mechanism by which mucositis develops and resolves, which is based on four phases: an initial inflammatory/vascular phase; an epithelial phase; a ulcerative/bacteriological phase; and a healing phase. Expand
Effect of high-dose chemotherapy on intestinal permeability in humans.
TLDR
It is concluded that chemotherapy given for malignant disease is associated with a transient abnormality in intestinal sugar permeability, which peaks at 7 days after treatment and is composed of both mono- and di-saccharide absorption abnormalities. Expand
Mucositis: Its Occurrence, Consequences, and Treatment in the Oncology Setting.
TLDR
Mucositis induced by antineoplastic drugs is an important, dose-limiting, and costly side effect of cancer therapy and can also have a significant economic cost in the autologous and allogeneic bone marrow transplant settings for hematologic malignancies. Expand
Management of Chemotherapy-Induced Adverse Effects in the Treatment of Colorectal Cancer
TLDR
Supportive measures for alleviation of the adverse effects of fluorouracil, raltitrexed, irinotecan and oxaliplatin, respectively, are described, based on study results. Expand
Overview of chemotherapy-induced diarrhea.
  • C. Viele
  • Medicine
  • Seminars in oncology nursing
  • 2003
TLDR
Through ongoing, regular patient contact, the oncology nurse is uniquely situated to monitor patients for the development of CID, assess its severity, and provide guidance to the health care team on the patient's status. Expand
Control of chemotherapy-induced diarrhoea with octreotide in patients receiving 5-fluorouracil.
TLDR
Octreotide seems to be an effective agent in the management of chemotherapy related diarrhoea following chemotherapy with 5-fluorouracil/leucovorin or interferon alpha (Machover's regimen) combination. Expand
The biological basis for the attenuation of mucositis: the example of interleukin-11
TLDR
Interleukin-11, a pleotropic cytokine, has a range of activities which are potentially relevant to mucositis and has been used successfully to modify the development, severity and course of mucosiositis in an animal model which closely mimics the equivalent human condition. Expand
Management of acute cancer treatment-induced diarrhea.
TLDR
Whatever therapy is chosen, the goal must be to quickly control this debilitating and potentially life-threatening side effect so that primary chemotherapy and/or radiation therapy may be resumed and completed. Expand
...
1
2
3
4
5
...